Estradiol Patent Expiration
Estradiol was first introduced by Novartis Pharmaceuticals Corp
Estradiol Patents
Given below is the list of patents protecting Estradiol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Imvexxy | US11266661 | Vaginal inserted estradiol pharmaceutical compositions and methods | Feb 02, 2034 | Mayne Pharma |
| Imvexxy | US10258630 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10398708 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10471072 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10537581 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10568891 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10668082 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10806697 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10835487 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US10888516 | Soluble estradiol capsule for vaginal insertion | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11065197 | Soluble estradiol capsule for vaginal insertion | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11116717 | Soluble estradiol capsule for vaginal insertion | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11123283 | Soluble estradiol capsule for vaginal insertion | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11241445 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11246875 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11304959 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11351182 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US11497709 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US9180091 | Soluble estradiol capsule for vaginal insertion | Nov 21, 2032 | Mayne Pharma |
| Imvexxy | US9289382 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
| Minivelle | US8231906 | Transdermal estrogen device and delivery | Jul 04, 2030 | Noven |
| Minivelle | US9724310 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
| Minivelle | US9730900 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
| Minivelle | US9833419 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
| Vagifem | US7018992 | Hormone composition |
Sep 17, 2022
(Expired) | Novo Nordisk Inc |
| Elestrin | US7198801 | Formulations for transdermal or transmucosal application |
Jun 25, 2022
(Expired) | Viatris |
| Evamist | US6978945 | Dispensing device |
Nov 30, 2021
(Expired) | Padagis Us |
| Elestrin | US7470433 | Formulations for transdermal or transmucosal application |
Aug 03, 2021
(Expired) | Viatris |
| Minivelle | US6841716 | Patch |
Apr 27, 2020
(Expired) | Noven |
| Menostar | US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov 21, 2017
(Expired) | Bayer Hlthcare |
| Menostar | US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov 21, 2017
(Expired) | Bayer Hlthcare |
| Vagifem | US5860946 | Instrument for inserting a suppository |
Jul 01, 2017
(Expired) | Novo Nordisk Inc |
| Evamist | US6299900 | Dermal penetration enhancers and drug delivery systems involving same |
Feb 19, 2017
(Expired) | Padagis Us |
| Evamist | US6818226 | Dermal penetration enhancers and drug delivery systems involving same |
Feb 19, 2017
(Expired) | Padagis Us |
| Evamist | US6923983 | Transdermal delivery of hormones |
Feb 19, 2017
(Expired) | Padagis Us |
| Minivelle | US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines |
Aug 12, 2014
(Expired) | Noven |
| Minivelle | US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug 12, 2014
(Expired) | Noven |
| Vivelle-dot | US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug 12, 2014
(Expired) | Sandoz |
| Minivelle | US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan 07, 2014
(Expired) | Noven |
| Vivelle-dot | US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan 07, 2014
(Expired) | Sandoz |
| Vivelle-dot | US5474783 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec 12, 2012
(Expired) | Sandoz |
| Vivelle-dot | US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec 12, 2012
(Expired) | Sandoz |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Estradiol's patents.
Latest Legal Activities on Estradiol's Patents
Given below is the list recent legal activities going on the following patents of Estradiol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical
| 28 Mar, 2006 | US7018992 |
| Recordation of Patent Grant Mailed Critical
| 28 Mar, 2006 | US7018992 |
| Issue Notification Mailed Critical
| 08 Mar, 2006 | US7018992 |
| Receipt into Pubs | 23 Feb, 2006 | US7018992 |
| Dispatch to FDC | 22 Feb, 2006 | US7018992 |
| Application Is Considered Ready for Issue Critical
| 22 Feb, 2006 | US7018992 |
| Receipt into Pubs | 20 Jan, 2006 | US7018992 |
| Printer Rush- No mailing | 27 Sep, 2005 | US7018992 |
| Pubs Case Remand to TC Critical
| 06 Sep, 2005 | US7018992 |
| Workflow - File Sent to Contractor | 03 Jun, 2005 | US7018992 |
About Veterinary Estradiol
Estradiol is used in a drug marketed by 1 company: Elanco Us Inc.
Other drugs containing Estradiol are: Compudose , encore .
Estradiol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Estradiol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
